Alan A. Musso - Jan 17, 2024 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role: Chief Financial Officer
Signature: /s/ Greg Tourangeau as attorney-in-fact for Alan Musso
Stock symbol: FULC
Transactions as of: Jan 17, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/19/2024, 04:15 PM
Previous filing: Nov 2, 2023
Next filing: Jan 30, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FULC	Stock Option (right to buy)	Award	$0	+61.8K		$0.00	61.8K	Jan 17, 2024	Common Stock	61.8K	$4.01	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This performance-based stock option was granted on August 7, 2023 and is subject to the achievement of certain pre-defined performance objectives pertaining to financial and investor relations goals within six months from the grant date, and subject to Mr. Musso continuing to be an "eligible participant" (as defined in Fulcrum Therapeutics, Inc.'s 2022 Inducement Stock Incentive Plan) through the vesting date. All performance objectives were met on January 17, 2024.

Content

This performance-based stock option was granted on August 7, 2023 and is subject to the achievement of certain pre-defined performance objectives pertaining to financial and investor relations goals within six months from the grant date, and subject to Mr. Musso continuing to be an "eligible participant" (as defined in Fulcrum Therapeutics, Inc.'s 2022 Inducement Stock Incentive Plan) through the vesting date. All performance objectives were met on January 17, 2024.